Licensable Assets - Overview

 A breakthrough in targeted therapeutics for acute myeloid leukemia and non-Hodgkin lymphoma. This innovative compound simultaneously inhibits PIM1/2/3 and CDK2/4/6 kinases, disrupting critical downstream signaling pathways that drive tumor cell differentiation and proliferation. 

 A breakthrough antibody-drug conjugate (ADC) targeting DLL3 for small cell lung cancer (SCLC) and other neuroendocrine tumors 

 A breakthrough approach in hematologic oncology, simultaneously targeting the FLT3 and CSF1R pathways to address both tumor cells and the immunosuppressive tumor microenvironment. This dual mechanism offers a differentiated therapeutic strategy for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). 

 Transforming cardiovascular and oncology treatment with the first oral small molecule PCSK9 inhibitor, delivering unmatched patient convenience and expanded access to life-saving therapy. 

 Polysaccharide Drug Conjugate

 First-in-class, IND-ready, anti-PD-L1 ADC with targeted cytotoxic delivery and immune checkpoint inhibition 

Innovative Platform and Pipeline: Transforming cancer treatment through tumor-specific activation technology. 

 Clinical-stage antisense oligonucleotide (ASO) therapeutic targeting AKT-1, with potential across a range of cancer types.  

 Proprietary CpG-ODN LNP formulation functioning as a TLR9 agonist designed to reinvigorate anti-tumor immunity. 

 First-in-class Thyromimetic MOA; activates hair follicle stem cells.   

With dual IND approvals from both the FDA (January 2025) and CDE (March 2025), it is poised to enter first-in-human trials in the near term across multiple advanced solid tumor indications including HNSCC, Sarcoma, and Osteosarcoma. Phase 1 first-in-human trials are imminent, with Phase 2 initiation anticipated in late 2026.

 Targets both the TH2 and TH1 pathways, the primary drivers of AD  pathology. This differentiated dual-inhibitor approach is designed to deliver  broader and more durable therapeutic response than single-pathway  agents.